Literature DB >> 7093111

The effect of fever on antipyrine metabolism in children.

J S Forsyth, T A Moreland, G W Rylance.   

Abstract

1 The elimination of antipyrine from saliva was measured in six children aged 5 months to 5 years during fever and during a control period 2-4 weeks after the cessation of fever. 2 The mean (+/- s.d.) saliva antipyrine clearance during fever, 32 +/- 13 ml kg-1 h-1, was nearly 50% less than that when the children were afebrile, 50 +/- 22 ml kg-1 h-1 (P less than 0.02). The mean saliva antipyrine half-life during fever, 15.20 +/- 5.40 h, was almost twice as long as that found when body temperature was normal, 9.18 +/- 2.49 h (P less than 0.01). The apparent volume of distribution of antipyrine was not significantly affected by fever. 3 These findings indicate that drug metabolising ability in children is impaired during fever.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7093111      PMCID: PMC1402021          DOI: 10.1111/j.1365-2125.1982.tb01871.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

1.  Effects of etiocholanolone-induced fever on plasma antipyrine half-lives and metabolic clearance.

Authors:  R J Elin; E S Vesell; S M Wolff
Journal:  Clin Pharmacol Ther       Date:  1975-04       Impact factor: 6.875

Review 2.  Factors influencing antipyrine elimination.

Authors:  I H Stevenson
Journal:  Br J Clin Pharmacol       Date:  1977-06       Impact factor: 4.335

Review 3.  Fever.

Authors:  E Atkins; P Bodel
Journal:  N Engl J Med       Date:  1972-01-06       Impact factor: 91.245

4.  The almost complete hepatic extraction of propranolol during intravenous administration in the dog.

Authors:  D G Shand; G H Evans; A S Nies
Journal:  Life Sci I       Date:  1971-12-15

5.  Genetic control of drug levels in man: antipyrine.

Authors:  E S Vesell; J G Page
Journal:  Science       Date:  1968-07-05       Impact factor: 47.728

6.  Drug metabolism in normal children, lead-poisoned children, and normal adults.

Authors:  A P Alvares; S Kapelner; S Sassa; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1975-02       Impact factor: 6.875

7.  Quinine disposition during malaria and during induced fever.

Authors:  G M Trenholme; R L Williams; K H Rieckmann; H Frischer; P E Carson
Journal:  Clin Pharmacol Ther       Date:  1976-04       Impact factor: 6.875

8.  Changes in drug metabolism in children with thyroid disorders.

Authors:  P Saenger; A B Rifkind; M I New
Journal:  J Clin Endocrinol Metab       Date:  1976-01       Impact factor: 5.958

9.  Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme induction and increased hepatic blood flow.

Authors:  R A Branch; D G Shand; G R Wilkinson; A S Nies
Journal:  J Clin Invest       Date:  1974-04       Impact factor: 14.808

10.  Drug interactions with warfarin: studies with dichloralphenazone, chloral hydrate and phenazone (antipyrine).

Authors:  A Breckenridge; M L Orme; S Thorgeirsson; D S Davies; R V Brooks
Journal:  Clin Sci       Date:  1971-04       Impact factor: 6.124

View more
  8 in total

1.  Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance.

Authors:  B J Gurley; G W Barone; K Yamashita; S Polston; M Estes; A Harden
Journal:  Pharm Res       Date:  1997-01       Impact factor: 4.200

2.  Pharmacokinetics of oral and intravenous ofloxacin in children with multidrug-resistant typhoid fever.

Authors:  D B Bethell; N P Day; N M Dung; C McMullin; H T Loan; D T Tam; L T Minh; N T Linh; N Q Dung; H Vinh; A P MacGowan; L O White; N J White
Journal:  Antimicrob Agents Chemother       Date:  1996-09       Impact factor: 5.191

3.  Antipyrine clearance in children from single saliva samples.

Authors:  S Loft; O Haxholdt; M Døssing
Journal:  Br J Clin Pharmacol       Date:  1985-05       Impact factor: 4.335

Review 4.  Antibiotic pharmacokinetics in cystic fibrosis. Differences and clinical significance.

Authors:  R de Groot; A L Smith
Journal:  Clin Pharmacokinet       Date:  1987-10       Impact factor: 6.447

5.  Bupivacaine kinetics during hyperthermia in rats.

Authors:  B Bruguerolle; X Roucoules; L Attolini; A M Lorec
Journal:  Can J Anaesth       Date:  1994-03       Impact factor: 5.063

Review 6.  Clinical pharmacokinetics in infants and children. A reappraisal.

Authors:  G L Kearns; M D Reed
Journal:  Clin Pharmacokinet       Date:  1989       Impact factor: 6.447

7.  Immunological response as a source to variability in drug metabolism and transport.

Authors:  Hege Christensen; Monica Hermann
Journal:  Front Pharmacol       Date:  2012-02-10       Impact factor: 5.810

8.  Impact of Inflammation on Cytochromes P450 Activity in Pediatrics: A Systematic Review.

Authors:  Camille Lenoir; Frédérique Rodieux; Jules A Desmeules; Victoria Rollason; Caroline F Samer
Journal:  Clin Pharmacokinet       Date:  2021-08-31       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.